|
WO2021064590A1
|
|
Diacylglycerol acyltransferase 2 inhibitor
|
|
WO2021059181A1
|
|
Neisseria meningitidis compositions and methods thereof
|
|
WO2021059136A1
|
|
Polyheterocyclic modulators of sting (stimulator of interferon genes)
|
|
WO2021048736A1
|
|
Treatment of hidradenitis with jak inhibitors
|
|
WO2021014360A1
|
|
Oral modified release dosage forms
|
|
US2021017172A1
|
|
Toll-like receptor agonists
|
|
WO2021001741A1
|
|
Improvements to wash solutions for protein a chromatography in an antibody purification process
|
|
UY38768A
|
|
BCKDK INHIBITORS
|
|
WO2020261178A1
|
|
Methods of treating duchenne muscular dystrophy using aav mini-dystrophin gene therapy
|
|
WO2020261144A1
|
|
5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases
|
|
WO2020254989A1
|
|
Cycloalkyl and heterocycloalkyl benzisoxazole sulfonamide derivatives
|
|
WO2020254946A1
|
|
Benzisoxazole sulfonamide derivatives
|
|
WO2020240360A1
|
|
Combination therapies using cdk inhibitors
|
|
WO2020239558A1
|
|
Combination therapies using cdk inhibitors
|
|
WO2020234726A1
|
|
Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
|
|
WO2020223512A1
|
|
Real-time tracking and management of standard workflows
|
|
US2020331909A1
|
|
Anti-proliferative agents for treating pah
|
|
WO2020208502A1
|
|
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
|
WO2020201985A1
|
|
Compositions and methods for eliciting an immune response against clostridium difficile
|
|
JP2020146032A
|
|
Methods for Purifying Bacterial Polysaccharides
|
